Sydney: Scientists in Australia have developed the next generation of nanokana to make the treatment of triple-negative breast cancer (TNBC) more effective. The disease is considered one of the most aggressive and deadly forms of breast cancer.

Researchers at the Australian Institute for Bio-Engineering and Nanotechnology (AIBN), the University of Queensland, have designed iron-based highly small nanocations, called “Nano-Edguents”. These nanocations can help fight against the tumor by strengthening the body's immune system.

How will Nano-Edguents work? AIBN professor Yu Chengzhong reported that compared to other breast cancer, TNBC does not have some special proteins targeted by traditional remedies, which makes the treatment challenging.

“Although immunotherapy can be effective against cancer, its success rate in TNBC is very low. Our research is trying to overcome this deficiency,” he said.

Nanocations increase the ability to attack the tumor by activating T-cells of the immune system. The research has the support of the National Health and Medical Research Council of 3 million Australian Dollars ($ 1.89 million) (NHMRC) grant.

future prospects This study can be useful not only for TNBC, but also in the treatment of other aggressive cancer such as ovarian cancer.

AIBN director Alan Rowan said, “This research will carry forward the boundaries of science and find innovative remedies that can change our way of fighting this cancer. This will give new hope to thousands of women.”